FHTX

Investor Moves

Name	Value	Action	Change	Price	Last Price
Steven CohenPoint72 $132k27.6k shares TrimQ1 2026 $202k $5.49 $5.19
Ken GriffinCitadel Advisors $956k200k shares TrimQ1 2026 $28k $5.49 $5.19
Jim SimonsRenaissance Technologies $2M406.4k shares AddQ1 2026 $335k $5.49 $5.19
Steven CohenPoint72 $-1.5M TrimQ4 2025 $1M $4.53 $5.19
Ken GriffinCitadel Advisors $925.5K AddQ4 2025 $925k $4.53 $5.19
Jim SimonsRenaissance Technologies $1.0M AddQ4 2025 $1M $4.53 $5.19

Insider Trades

Name	Value	Action	Price	Last Price
Costa CarlosChief People Officer $359k35.8k shares SellSep 20, 2024 $10.04 $5.19
Costa CarlosChief People Officer $8.7k857 shares SellSep 23, 2024 $10.17 $5.19
Costa CarlosChief People Officer $116k11.6k shares SellSep 18, 2024 $10.05 $5.19
Costa CarlosChief People Officer $4k400 shares SellSep 16, 2024 $10.00 $5.19
Costa CarlosChief People Officer $103k10.3k shares SellSep 17, 2024 $10.04 $5.19
Bellon Steven F.Chief Scientific Officer $190k20k shares SellSep 9, 2024 $9.50 $5.19

News

seekingalpha.comFoghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9

globenewswire.comFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026globenewswire.comJun 5

globenewswire.comFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in Mayglobenewswire.comMay 12

zacks.comFoghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 7

globenewswire.comFoghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Updateglobenewswire.comMay 7

Trade FHTX

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.

CEO: Adrian H. Gottschalk
IPO Date: Oct 23, 2020

Market Data

Open: $4.12
High: $4.17
Low: $4.05
Volume: 175.9K
Avg Volume: 146.2K
52W High: $6.95
52W Low: $3.27

Valuation

Market Cap: $243.7M
Enterprise Value: $196.7M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$86.1M
Revenue: $30.9M
Net Income: -$74.3M
Cash: $80.9M
Debt: $41.3M

Events

EarningsAug 4

EPS est. -0.23